The Phelan-McDermid Syndrome Foundation is bringing together families, scientists, clinicians, industry partners, and other invested parties this July for the first time since 2018. Our agenda is based on our tripartite mission in Phelan-McDermid syndrome: to CURE(drive research breakthroughs), CARE(improve medical care), and CONNECT(support families).
The purpose of the study is to look at the safety, tolerability, and efficacy of NNZ-2591 in the treatment of children…
Neuren has released a statement that the drug was found to be generally safe at the dose tested, having no serious adverse effects.
Neuren has released a statement that the drug was found to be generally safe at the dose tested, having no serious adverse effects.
Data has emerged that a subset of individuals with Phelan-McDermid syndrome (PMS) experience devastating psychiatric symptoms, such as regression, bipolar disorder, and catatonia.
We are seeking highly novel grant applications which explore an understudied area of Phelan-McDermid syndrome (PMS) research. Successful proposals will open new avenues of research in the field. Applications with clinical relevance will be preferred. Applications can be focused on any topic, but areas of special interest to families include: research across other neurodevelopmental disorders, development of tools for monitoring or managing symptoms, peripheral nervous system studies, identification of new drug candidates, implication of new cell types, and understanding of genes aside from SHANK3
